ATE243513T1 - Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers - Google Patents

Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers

Info

Publication number
ATE243513T1
ATE243513T1 AT97922668T AT97922668T ATE243513T1 AT E243513 T1 ATE243513 T1 AT E243513T1 AT 97922668 T AT97922668 T AT 97922668T AT 97922668 T AT97922668 T AT 97922668T AT E243513 T1 ATE243513 T1 AT E243513T1
Authority
AT
Austria
Prior art keywords
photosensitizer
prolactin
killing
growth inhibition
solid tumors
Prior art date
Application number
AT97922668T
Other languages
English (en)
Inventor
Anthony H Cincotta
Louis Cincotta
Original Assignee
Gen Hospital Corp
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Harvard College filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE243513T1 publication Critical patent/ATE243513T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97922668T 1996-05-01 1997-04-15 Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers ATE243513T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1661996P 1996-05-01 1996-05-01
PCT/US1997/007577 WO1997040829A1 (en) 1996-05-01 1997-04-15 Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy

Publications (1)

Publication Number Publication Date
ATE243513T1 true ATE243513T1 (de) 2003-07-15

Family

ID=21778086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97922668T ATE243513T1 (de) 1996-05-01 1997-04-15 Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers

Country Status (9)

Country Link
US (2) US20010049350A1 (de)
EP (1) EP0910365B1 (de)
JP (1) JP2000509398A (de)
AT (1) ATE243513T1 (de)
CA (1) CA2253207C (de)
DE (1) DE69723077T2 (de)
DK (1) DK0910365T3 (de)
ES (1) ES2205215T3 (de)
WO (1) WO1997040829A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
EP1187609A4 (de) * 1999-06-03 2003-07-02 Gen Hospital Corp Behandlung und analyse proliferativer erkrankungen
DE10229456A1 (de) * 2002-07-01 2004-02-05 Wank, Rudolf, Prof. Dr.med. Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen
CN101516255A (zh) * 2006-09-13 2009-08-26 皇家飞利浦电子股份有限公司 用于自动调整褪黑素的剂量和/或递送褪黑素的装置
CN101754753A (zh) * 2007-05-24 2010-06-23 纽约市哥伦比亚大学托管会 褪黑素的持久释放配方
US9724069B2 (en) * 2009-12-22 2017-08-08 Biolitec Unternehmensbeteiligungs Ii Ag Tissue resection under image guidance/control
US8759289B2 (en) 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP2925337B1 (de) * 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
DK3445362T3 (da) 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
WO2019079623A1 (en) 2017-10-18 2019-04-25 Veroscience Llc ENHANCED BROMOCRIPTINE FORMULATIONS
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods

Also Published As

Publication number Publication date
EP0910365A1 (de) 1999-04-28
CA2253207C (en) 2008-12-30
JP2000509398A (ja) 2000-07-25
DE69723077D1 (de) 2003-07-31
DE69723077T2 (de) 2004-05-06
US20040102383A1 (en) 2004-05-27
EP0910365B1 (de) 2003-06-25
ES2205215T3 (es) 2004-05-01
EP0910365A4 (de) 1999-12-01
DK0910365T3 (da) 2003-10-20
WO1997040829A1 (en) 1997-11-06
CA2253207A1 (en) 1997-11-06
US20010049350A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE69723077D1 (de) Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers
NO974497L (no) Biologisk vevstimulering ved optisk energi
EP0637976A1 (de) Behandlung mittels laser.
ES2160173T3 (es) Nuevo derivado de rodamina para la terapia fotodinamica de cancer y purgacion en vitro de leucemia.
FI981954A0 (fi) Parannettu näkökyky silmän fotodynaamisen terapian avulla
AU732673C (en) Device for the photodynamic treatment of living beings and of the organs thereof
DE69711894D1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
WO2007016287A3 (en) Pdt treatment method for cellulites and cosmetic use
ATE277515T1 (de) Verfahren zur behandlung von pigmentierten krebszellen durch photodynamische therapie
KR20120018050A (ko) 광치료기
SE9101807L (sv) Framstaellning och anvaendning av porfyriner
Moan et al. Photodynamic inactivation of cancer cells in vitro. Effect of irradiation temperature and dose fractionation
DE60001629D1 (de) Therapeutische zusammensetzungen fur knochenstoffwechselstörungen oder knochenmetastasen enthaltend einen photosensitizer und ein bisphosphonat
Wulf et al. Counteracting side-effects of photodynamic therapy for actinic keratoses
Lim et al. Phototoxicity induced by hematoporphyrin derivative in C5‐deficient, mast cell‐deficient and leukopenic mice
RU94007018A (ru) Способ лечения больных хроническим простатитом
CN216255908U (zh) 一种美容嫩肤美甲灯
NO973251D0 (no) Fremgangsmåte for å forebygge transplantavstötelse
Cha et al. Effect of a portable light emitting diode device on wound healing in a rat model
RU95119783A (ru) Способ биостимуляции сельскохозяйственной птицы
RU2004128804A (ru) Способ лечения гнойных ран
DE69841892D1 (de) Verwendung von Maleimidderivaten in wasserverträglichen Energie-härtbaren Zusammensetzungen
Al-Zamily et al. The Effect of Helium-Neon Laser, Using Different Methods and Frequencies of Radiation, on Wound Healing
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
Kushibiki Control of Cell Function by Photobiomodulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910365

Country of ref document: EP